Saxon Interests Inc. Acquires 94 Shares of Amgen Inc. (NASDAQ:AMGN)

Saxon Interests Inc. lifted its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 8.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,176 shares of the medical research company’s stock after buying an additional 94 shares during the quarter. Saxon Interests Inc.’s holdings in Amgen were worth $261,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of AMGN. Moneta Group Investment Advisors LLC grew its stake in Amgen by 83,875.6% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after acquiring an additional 7,532,031 shares during the period. Norges Bank acquired a new stake in Amgen in the 4th quarter valued at $1,351,778,000. Envestnet Asset Management Inc. increased its stake in Amgen by 216.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,690,718 shares of the medical research company’s stock valued at $228,997,000 after purchasing an additional 1,839,455 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Amgen by 158.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after buying an additional 1,806,456 shares during the last quarter. Finally, Morgan Stanley lifted its stake in shares of Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after buying an additional 1,523,665 shares in the last quarter. Institutional investors own 74.44% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, EVP Murdo Gordon sold 9,558 shares of Amgen stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $262.43, for a total value of $2,508,305.94. Following the completion of the transaction, the executive vice president now directly owns 44,308 shares in the company, valued at $11,627,748.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.57% of the company’s stock.

Amgen Stock Performance

Amgen stock traded up $0.82 during trading on Tuesday, hitting $263.97. The stock had a trading volume of 727,909 shares, compared to its average volume of 2,449,523. The company has a quick ratio of 2.48, a current ratio of 2.77 and a debt-to-equity ratio of 8.76. The stock’s 50 day moving average is $248.12 and its two-hundred day moving average is $237.72. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $296.67. The stock has a market cap of $141.20 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 3.28 and a beta of 0.61.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share for the quarter, topping the consensus estimate of $4.44 by $0.56. Amgen had a return on equity of 196.60% and a net margin of 30.02%. The company had revenue of $7 billion during the quarter, compared to the consensus estimate of $6.66 billion. During the same quarter in the prior year, the company earned $4.65 EPS. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. As a group, analysts predict that Amgen Inc. will post 18.35 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Friday, August 18th were paid a dividend of $2.13 per share. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.23%. The ex-dividend date of this dividend was Thursday, August 17th. Amgen’s payout ratio is currently 57.45%.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 8th. Barclays lowered their price objective on Amgen from $225.00 to $210.00 in a research note on Tuesday, July 11th. Mizuho lifted their target price on Amgen from $214.00 to $223.00 and gave the company a “neutral” rating in a research report on Monday, August 14th. HSBC initiated coverage on Amgen in a research report on Wednesday, September 6th. They issued a “buy” rating and a $320.00 price target for the company. Finally, Credit Suisse Group reduced their target price on shares of Amgen from $220.00 to $200.00 in a research note on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $265.44.

Check Out Our Latest Stock Report on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.